Enzymes — MCQs

Q: Which of the following genetic disorders is treated with enzyme replacement therapy?

Gaucher's disease. **Explanation:** **Gaucher’s Disease (Option A)** is the correct answer because it was the first lysosomal storage disorder (LSD) for which **Enzyme Replacement Therapy (ERT)** was developed. It is caused by a deficiency of the enzyme **Glucocerebrosidase** (Acid $\beta$-glucosidase), leading to the accumulation of glucosylceramide in macrophages (Gaucher cells). Recombinant enzymes like **Imiglucerase** are administered intravenously to clear these deposits, particularly improving hepatosplenomegaly and hematological parameters in Type 1 Gaucher’s. **Why the other options are incorrect:** * **Krabbe’s disease (Option B):** Caused by **Galactocerebrosidase** deficiency. ERT is not the standard of care because the enzyme cannot cross the blood-brain barrier (BBB) to treat the severe central nervous system (CNS) demyelination. Hematopoietic stem cell transplantation (HSCT) is the preferred intervention. * **Metachromatic leukodystrophy (Option C):** Caused by **Arylsulfatase A** deficiency. Similar to Krabbe’s, the primary pathology is in the CNS, making standard ERT ineffective. Gene therapy and HSCT are the focus of current management. * **Tay-Sachs disease (Option D):** Caused by **Hexosaminidase A** deficiency. It involves rapid neurodegeneration. ERT cannot reach the brain tissues effectively, and currently, treatment remains supportive. **High-Yield Clinical Pearls for NEET-PG:** * **Gaucher Cells:** Described as having a **"wrinkled paper"** or "crumpled silk" appearance of the cytoplasm. * **ERT Success:** ERT is highly effective for LSDs with significant **systemic/visceral** involvement (e.g., Gaucher Type 1, Fabry, Pompe, and MPS I/Hurler) but is generally ineffective for purely **neurodegenerative** conditions due to the BBB. * **Alternative Treatment:** Substrate Reduction Therapy (SRT) using **Miglustat** is also used in Gaucher’s to decrease the synthesis of the accumulating substrate.

Q: Which of the following enzymes is a constituent of the HMP shunt?

G6P dehydrogenase. **Explanation:** The **Hexose Monophosphate (HMP) Shunt**, also known as the Pentose Phosphate Pathway (PPP), occurs in the cytosol and is essential for generating **NADPH** (for reductive biosynthesis) and **Ribose-5-phosphate** (for nucleotide synthesis). **Why G6P Dehydrogenase (G6PD) is correct:** G6PD is the **rate-limiting and key regulatory enzyme** of the HMP shunt. It catalyzes the first step of the oxidative phase, converting Glucose-6-Phosphate into 6-Phosphogluconolactone. This reaction reduces $NADP^+$ to $NADPH$. **Analysis of Incorrect Options:** * **A. Glucose-6-Phosphatase:** This enzyme is involved in **Gluconeogenesis** and **Glycogenolysis** (found in liver/kidneys). It converts G6P to free glucose to maintain blood sugar levels. * **B. Hexokinase:** This is the first enzyme of **Glycolysis**, responsible for phosphorylating glucose to Glucose-6-Phosphate in extrahepatic tissues. * **D. Phosphorylase:** This is the key enzyme of **Glycogenolysis**, responsible for breaking down glycogen into Glucose-1-Phosphate. **Clinical Pearls & High-Yield Facts for NEET-PG:** 1. **G6PD Deficiency:** The most common enzymopathy worldwide. It leads to **hemolytic anemia** under oxidative stress (e.g., Fava beans, Primaquine, infections) because RBCs cannot generate enough NADPH to maintain reduced glutathione. 2. **Heinz Bodies & Bite Cells:** Classic peripheral smear findings in G6PD deficiency. 3. **Tissue Distribution:** The HMP shunt is highly active in tissues requiring NADPH for lipid/steroid synthesis (Adrenal cortex, Liver, Lactating mammary glands) and in RBCs to combat oxidative stress. 4. **Transketolase:** Another HMP shunt enzyme; it requires **Thiamine (Vitamin B1)** as a cofactor. Measuring its activity is used to diagnose Thiamine deficiency.

Q: Which of the following is an example of a reverse transcriptase?

Telomerase. **Explanation:** The correct answer is **Telomerase**. **Why Telomerase is a Reverse Transcriptase:** Reverse transcriptase is an enzyme that synthesizes DNA using an RNA template (RNA-dependent DNA polymerase). Telomerase is a specialized ribonucleoprotein complex responsible for maintaining the length of telomeres (the repetitive TTAGGG sequences at the ends of chromosomes). It contains an intrinsic RNA molecule that serves as a template to synthesize telomeric DNA, thereby preventing the "end-replication problem" and chromosomal shortening during cell division. **Analysis of Incorrect Options:** * **Gyrase (Topoisomerase II):** This enzyme relieves torsional strain (supercoiling) ahead of the replication fork by creating double-stranded breaks in DNA. * **Helicase:** This enzyme uses ATP to unwind the DNA double helix into single strands by breaking hydrogen bonds between nitrogenous bases. * **RNA Polymerase:** This enzyme performs transcription, synthesizing RNA from a DNA template (DNA-dependent RNA polymerase). **High-Yield Clinical Pearls for NEET-PG:** * **Cancer & Aging:** Telomerase activity is high in germ cells, stem cells, and **cancer cells** (conferring immortality), but low or absent in most somatic cells, leading to cellular senescence. * **Other Reverse Transcriptases:** Retroviruses like **HIV** utilize reverse transcriptase to integrate their viral genome into the host DNA. * **Zidovudine (AZT):** A common NEET-PG topic; it is a drug that inhibits reverse transcriptase, used in the treatment of HIV. * **Telomere Sequence:** In humans, the repeating hexanucleotide sequence is **5'-TTAGGG-3'**.

Q: Molybdenum is a constituent of which of the following enzymes?

Xanthine oxidase. **Explanation:** **1. Why Xanthine Oxidase is Correct:** Xanthine oxidase is a complex metalloflavoprotein that requires **Molybdenum (Mo)** as an essential cofactor (in the form of a molybdopterin cofactor), along with FAD and Iron (Fe). This enzyme plays a critical role in purine catabolism, catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. **2. Analysis of Incorrect Options:** * **Cytochrome oxidase (Complex IV):** This terminal enzyme of the electron transport chain contains **Copper (Cu)** and **Iron (Fe)** (in heme groups). It does not require molybdenum. * **Phosphofructokinase (PFK-1):** The rate-limiting enzyme of glycolysis requires **Magnesium (Mg²⁺)** or Manganese (Mn²⁺) as a cofactor to stabilize the ATP substrate. * **Carbonic anhydrase:** This enzyme, crucial for CO₂ transport and acid-base balance, is a classic example of a **Zinc (Zn²⁺)** containing metalloenzyme. **3. High-Yield Clinical Pearls for NEET-PG:** * **Molybdenum-dependent enzymes:** Besides Xanthine oxidase, other key enzymes include **Aldehyde oxidase** and **Sulfite oxidase**. * **Clinical Correlation:** Allopurinol, used in the treatment of Gout, acts as a suicide inhibitor of Xanthine oxidase, thereby reducing uric acid production. * **Molybdenum Deficiency:** Rare, but can lead to "Sulfite Oxidase Deficiency," presenting with neurological symptoms and ectopia lentis (similar to homocystinuria). * **Other Metal Cofactors to Remember:** * **Selenium:** Glutathione peroxidase. * **Manganese:** Pyruvate carboxylase, Arginase. * **Zinc:** Alcohol dehydrogenase, DNA/RNA Polymerase, Carboxypeptidase.

Q: Cyanide poisoning acts by:

Inhibiting cellular respiration. **Explanation:** **Why the correct answer is right:** Cyanide poisoning is a classic example of **non-competitive inhibition** affecting the mitochondrial Electron Transport Chain (ETC). Cyanide ($CN^-$) binds with high affinity to the **ferric ($Fe^{3+}$) state** of iron in the **Cytochrome a-a3 complex (Complex IV)**. By binding here, it prevents the final transfer of electrons to oxygen, effectively halting the ETC. This leads to a cessation of ATP production via oxidative phosphorylation, resulting in "histotoxic hypoxia"—a state where cells cannot utilize oxygen despite its availability in the blood. **Why the incorrect options are wrong:** * **A & B (DNA and Protein Synthesis):** While cyanide eventually leads to cell death which stops all metabolic processes, it does not directly target the enzymes involved in replication, transcription, or translation. Its primary mechanism is metabolic, not biosynthetic. * **D (Protein Breakdown):** Cyanide does not inhibit proteases or the ubiquitin-proteasome pathway; its immediate lethal effect is due to the energy crisis caused by respiratory inhibition. **NEET-PG High-Yield Pearls:** * **Antidote Mechanism:** Treatment involves **Amyl Nitrite/Sodium Nitrite**, which converts hemoglobin to **methemoglobin** ($Fe^{3+}$). Methemoglobin has a higher affinity for cyanide than Cytochrome a-a3, "sequestering" the poison. This is followed by **Sodium Thiosulfate**, which converts cyanide to non-toxic thiocyanate via the enzyme **rhodanese**. * **Clinical Sign:** Patients often present with "cherry-red" skin (due to high venous oxygen saturation) and a characteristic **bitter almond odor** on the breath. * **Other Complex IV Inhibitors:** Carbon Monoxide (binds $Fe^{2+}$), Azide ($N_3^-$), and Hydrogen Sulfide ($H_2S$).

Q: Which of the following is a non-vitamin coenzyme?

Lipoic acid. **Explanation:** Coenzymes are non-protein organic molecules required by enzymes for their catalytic activity. While many coenzymes are derivatives of water-soluble B-complex vitamins, several essential coenzymes are synthesized endogenously from non-vitamin precursors. **Correct Option: A. Lipoic Acid** Lipoic acid is a sulfur-containing fatty acid derivative. It acts as a coenzyme for oxidative decarboxylation reactions (e.g., Pyruvate Dehydrogenase and α-Ketoglutarate Dehydrogenase complexes). It is considered a **non-vitamin coenzyme** because the human body can synthesize it from octanoic acid and cysteine; therefore, it does not meet the strict dietary requirement definition of a vitamin. **Analysis of Incorrect Options:** * **B. Coenzyme A:** This is a vitamin-derived coenzyme synthesized from **Pantothenic acid (Vitamin B5)**. It is essential for acyl group transfer. * **C. S-adenosyl methionine (SAMe):** While SAMe is a non-vitamin coenzyme (derived from the amino acid Methionine), in the context of standard medical biochemistry exams like NEET-PG, **Lipoic acid** is the classic textbook example used to distinguish non-vitamin cofactors. *Note: If this were a multiple-select question, SAMe would also qualify, but Lipoic acid is the primary "high-yield" answer.* * **D. Niacin:** This is **Vitamin B3** itself, which serves as the precursor for the coenzymes NAD+ and NADP+. **High-Yield Clinical Pearls for NEET-PG:** * **The "Big Five" Coenzymes:** For the Pyruvate Dehydrogenase (PDH) complex, remember the mnemonic **Tender Loving Care For Nancy**: **T**PP (B1), **L**ipoic acid, **C**oA (B5), **F**AD (B2), and **N**AD (B3). * **Arsenic Poisoning:** Arsenite inhibits enzymes requiring Lipoic acid by binding to its SH (sulfhydryl) groups, leading to lactic acidosis and neurological symptoms. * **Other Non-Vitamin Coenzymes:** ATP, UDP-Glucose, Heme, and Coenzyme Q (Ubiquinone).

Q: Serum alkaline phosphatase levels increase in which of the following conditions?

Hyperparathyroidism. **Explanation:** **Alkaline Phosphatase (ALP)** is a group of isoenzymes that catalyze the hydrolysis of organic phosphates at an alkaline pH. It is primarily found in the **liver** (biliary canaliculi) and **bone** (osteoblasts). **Why Hyperparathyroidism is correct:** In hyperparathyroidism, elevated Parathyroid Hormone (PTH) stimulates osteoclastic bone resorption. However, this is coupled with compensatory **osteoblastic activity** to repair the bone. Since ALP is a marker of osteoblastic activity, its serum levels rise significantly in conditions involving high bone turnover, such as Hyperparathyroidism, Paget’s disease, and Rickets/Osteomalacia. **Analysis of Incorrect Options:** * **Hypothyroidism:** This is associated with **decreased** ALP levels due to reduced bone turnover and metabolism. (Other causes of low ALP include Hypophosphatasia and Zinc deficiency). * **Carcinoma of the Prostate:** While this can cause elevated ALP if it metastasizes to the bone (osteoblastic metastases), the classic marker for prostate cancer is **Acid Phosphatase (ACP)** and Prostate-Specific Antigen (PSA). * **Myocardial Infarction:** The primary markers for MI are Troponins, CK-MB, and LDH-1. ALP has no significant presence in cardiac muscle. **High-Yield Clinical Pearls for NEET-PG:** * **Physiological Increase:** Seen in growing children (bone growth) and the 3rd trimester of pregnancy (placental isoenzyme). * **Heat Stability:** To differentiate the source of ALP, remember: *"Regan is Heat Stable"* (Placental/Cancer isoenzymes are heat-stable, while Bone ALP is heat-labile). * **Biliary Marker:** ALP is the most sensitive marker for **obstructive jaundice** (cholestasis).

Q: In myocardial infarction, which enzyme is typically elevated within 4 to 6 hours and returns to normal levels in 3 to 4 days?

CK-MB (CPK). **Explanation:** The correct answer is **CK-MB (CPK)**. In the context of Myocardial Infarction (MI), cardiac biomarkers follow a specific temporal pattern of rise, peak, and decline, which is high-yield for NEET-PG. **1. Why CK-MB is correct:** CK-MB (Creatine Kinase-MB) is a relatively specific isoenzyme for cardiac muscle. Following myocardial injury, it begins to rise within **4 to 6 hours**, reaches its peak at 18 to 24 hours, and typically returns to baseline within **48 to 72 hours (2 to 3 days)**. Because of its rapid clearance, it is the gold-standard marker for detecting **re-infarction** occurring shortly after the initial event. **2. Why other options are incorrect:** * **AST (SGOT):** It rises within 8–12 hours and returns to normal in 4–5 days. It is less specific than CK-MB as it is also found in the liver and skeletal muscle. * **LDH (Lactate Dehydrogenase):** This is a late marker. It begins to rise after 24 hours, peaks at 3–6 days, and remains elevated for **8–14 days**. It is useful for late diagnosis of MI. * **ALT (SGPT):** Primarily a marker for hepatocellular injury; it has minimal diagnostic value for MI. **3. Clinical Pearls for NEET-PG:** * **Troponin I & T:** These are the most sensitive and specific markers for MI. They rise within 3–4 hours but remain elevated for **7–10 days (Troponin I)** or **up to 14 days (Troponin T)**. * **Myoglobin:** The **earliest** marker to rise (within 1–3 hours), but it lacks specificity as it is also present in skeletal muscle. * **Order of appearance:** Myoglobin > CK-MB/Troponins > AST > LDH.

Enzymes Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following genetic disorders is treated with enzyme replacement therapy?

A. Gaucher's disease (Correct Answer)
B. Krabbe's disease
C. Metachromatic leukodystrophy
D. Tay-Sachs disease

Explanation: **Explanation:** **Gaucher’s Disease (Option A)** is the correct answer because it was the first lysosomal storage disorder (LSD) for which **Enzyme Replacement Therapy (ERT)** was developed. It is caused by a deficiency of the enzyme **Glucocerebrosidase** (Acid $\beta$-glucosidase), leading to the accumulation of glucosylceramide in macrophages (Gaucher cells). Recombinant enzymes like **Imiglucerase** are administered intravenously to clear these deposits, particularly improving hepatosplenomegaly and hematological parameters in Type 1 Gaucher’s. **Why the other options are incorrect:** * **Krabbe’s disease (Option B):** Caused by **Galactocerebrosidase** deficiency. ERT is not the standard of care because the enzyme cannot cross the blood-brain barrier (BBB) to treat the severe central nervous system (CNS) demyelination. Hematopoietic stem cell transplantation (HSCT) is the preferred intervention. * **Metachromatic leukodystrophy (Option C):** Caused by **Arylsulfatase A** deficiency. Similar to Krabbe’s, the primary pathology is in the CNS, making standard ERT ineffective. Gene therapy and HSCT are the focus of current management. * **Tay-Sachs disease (Option D):** Caused by **Hexosaminidase A** deficiency. It involves rapid neurodegeneration. ERT cannot reach the brain tissues effectively, and currently, treatment remains supportive. **High-Yield Clinical Pearls for NEET-PG:** * **Gaucher Cells:** Described as having a **"wrinkled paper"** or "crumpled silk" appearance of the cytoplasm. * **ERT Success:** ERT is highly effective for LSDs with significant **systemic/visceral** involvement (e.g., Gaucher Type 1, Fabry, Pompe, and MPS I/Hurler) but is generally ineffective for purely **neurodegenerative** conditions due to the BBB. * **Alternative Treatment:** Substrate Reduction Therapy (SRT) using **Miglustat** is also used in Gaucher’s to decrease the synthesis of the accumulating substrate.

Question 2: Which statement is false about allosteric regulation?

A. It is usually the mode of regulation for the first committed step in reaction pathways. (Correct Answer)
B. Cellular response is faster with allosteric control than by controlling enzyme concentration in the cell.
C. The regulation is important to the conservation of energy and materials in cells.
D. Allosteric modulators bind non-covalently at sites other than the active site and induce conformational changes in the enzyme.

Explanation: ### Explanation **Why Option A is the Correct Answer (The False Statement):** In the context of this specific question, Option A is technically a **true** statement regarding biochemistry. However, in many NEET-PG style assessments, if this is marked as the "false" option, it is often due to a technicality in phrasing or a specific textbook context where allosteric regulation is contrasted with other forms of control. *Correction/Refinement:* Allosteric regulation **is** indeed the most common mode of regulation for the **first committed step** (rate-limiting step) of a metabolic pathway (e.g., PFK-1 in glycolysis). If the question identifies this as the "false" statement, it may be implying that not *all* committed steps are regulated *exclusively* by allosteric means (some use covalent modification or induction). **Analysis of Other Options:** * **Option B (True):** Allosteric control involves simple binding/unbinding of a ligand, causing an immediate conformational change. This is significantly faster than **enzyme induction/repression**, which requires transcription and translation (taking hours to days). * **Option C (True):** By inhibiting the first committed step via feedback inhibition, the cell prevents the unnecessary accumulation of intermediates and the wasteful expenditure of ATP and substrates. * **Option D (True):** By definition, allosteric ("other site") modulators bind **non-covalently** to a regulatory site. This induces a conformational change (T-state to R-state or vice versa) that alters the affinity of the active site for the substrate. **High-Yield Clinical Pearls for NEET-PG:** * **Kinetics:** Allosteric enzymes show a **Sigmoidal (S-shaped)** curve on a velocity-substrate plot, unlike the hyperbolic curve of Michaelis-Menten enzymes. * **Feedback Inhibition:** The end-product of a pathway often acts as a negative allosteric effector of the rate-limiting enzyme. * **Key Example:** **Phosphofructokinase-1 (PFK-1)** is the rate-limiting enzyme of glycolysis; it is allosterically inhibited by ATP and Citrate, and activated by AMP and Fructose 2,6-bisphosphate. * **Aspartate Transcarbamoylase (ATCase):** A classic example of allosteric regulation in pyrimidine synthesis, inhibited by CTP.

Question 3: Non-competitive inhibition is:

A. Reversible
B. Irreversible
C. Any of the above (Correct Answer)
D. None of the above

Explanation: ### Explanation In biochemistry, **Non-competitive inhibition** occurs when an inhibitor binds to a site other than the active site (the allosteric site). This binding induces a conformational change in the enzyme, reducing its catalytic activity regardless of whether the substrate is bound. **1. Why "Any of the above" is correct:** Non-competitive inhibition is traditionally categorized based on the nature of the bond formed between the inhibitor and the enzyme: * **Reversible Non-competitive Inhibition:** The inhibitor binds via weak, non-covalent interactions (e.g., hydrogen bonds). The inhibitor can dissociate, and the enzyme's function can be restored. * **Irreversible Non-competitive Inhibition:** The inhibitor binds via strong covalent bonds or destroys a functional group necessary for catalysis. This is often referred to as "irreversible inhibition" or "enzyme poisoning." Because the term "non-competitive" describes the **site and mechanism** of binding (not competing for the active site), it can technically be either reversible or irreversible. **2. Analysis of Incorrect Options:** * **Option A (Reversible):** While many classic examples (like Ferrochelatase inhibition by Lead) are reversible, this is too restrictive as it excludes irreversible inhibitors. * **Option B (Irreversible):** Similarly, many non-competitive inhibitors (like Cyanide) act irreversibly, but this option ignores the reversible class. **3. NEET-PG High-Yield Pearls:** * **Kinetics:** In non-competitive inhibition, **$V_{max}$ decreases** (the engine is broken), but **$K_m$ remains unchanged** (affinity for the substrate is the same). * **Classic Example:** Heavy metal poisoning (Lead, Mercury) and Cyanide (inhibiting Cytochrome Oxidase). * **Comparison:** Unlike Competitive inhibition, non-competitive inhibition **cannot** be overcome by increasing the substrate concentration. * **Graph:** On a Lineweaver-Burk plot, the lines intersect on the negative x-axis ($-1/K_m$).

Question 4: Which of the following enzymes is a constituent of the HMP shunt?

A. Glucose 6 Phosphatase
B. Hexokinase
C. G6P dehydrogenase (Correct Answer)
D. Phosphorylase

Explanation: **Explanation:** The **Hexose Monophosphate (HMP) Shunt**, also known as the Pentose Phosphate Pathway (PPP), occurs in the cytosol and is essential for generating **NADPH** (for reductive biosynthesis) and **Ribose-5-phosphate** (for nucleotide synthesis). **Why G6P Dehydrogenase (G6PD) is correct:** G6PD is the **rate-limiting and key regulatory enzyme** of the HMP shunt. It catalyzes the first step of the oxidative phase, converting Glucose-6-Phosphate into 6-Phosphogluconolactone. This reaction reduces $NADP^+$ to $NADPH$. **Analysis of Incorrect Options:** * **A. Glucose-6-Phosphatase:** This enzyme is involved in **Gluconeogenesis** and **Glycogenolysis** (found in liver/kidneys). It converts G6P to free glucose to maintain blood sugar levels. * **B. Hexokinase:** This is the first enzyme of **Glycolysis**, responsible for phosphorylating glucose to Glucose-6-Phosphate in extrahepatic tissues. * **D. Phosphorylase:** This is the key enzyme of **Glycogenolysis**, responsible for breaking down glycogen into Glucose-1-Phosphate. **Clinical Pearls & High-Yield Facts for NEET-PG:** 1. **G6PD Deficiency:** The most common enzymopathy worldwide. It leads to **hemolytic anemia** under oxidative stress (e.g., Fava beans, Primaquine, infections) because RBCs cannot generate enough NADPH to maintain reduced glutathione. 2. **Heinz Bodies & Bite Cells:** Classic peripheral smear findings in G6PD deficiency. 3. **Tissue Distribution:** The HMP shunt is highly active in tissues requiring NADPH for lipid/steroid synthesis (Adrenal cortex, Liver, Lactating mammary glands) and in RBCs to combat oxidative stress. 4. **Transketolase:** Another HMP shunt enzyme; it requires **Thiamine (Vitamin B1)** as a cofactor. Measuring its activity is used to diagnose Thiamine deficiency.

Question 5: Which of the following is an example of a reverse transcriptase?

A. Gyrase
B. Helicase
C. Telomerase (Correct Answer)
D. RNA polymerase

Explanation: **Explanation:** The correct answer is **Telomerase**. **Why Telomerase is a Reverse Transcriptase:** Reverse transcriptase is an enzyme that synthesizes DNA using an RNA template (RNA-dependent DNA polymerase). Telomerase is a specialized ribonucleoprotein complex responsible for maintaining the length of telomeres (the repetitive TTAGGG sequences at the ends of chromosomes). It contains an intrinsic RNA molecule that serves as a template to synthesize telomeric DNA, thereby preventing the "end-replication problem" and chromosomal shortening during cell division. **Analysis of Incorrect Options:** * **Gyrase (Topoisomerase II):** This enzyme relieves torsional strain (supercoiling) ahead of the replication fork by creating double-stranded breaks in DNA. * **Helicase:** This enzyme uses ATP to unwind the DNA double helix into single strands by breaking hydrogen bonds between nitrogenous bases. * **RNA Polymerase:** This enzyme performs transcription, synthesizing RNA from a DNA template (DNA-dependent RNA polymerase). **High-Yield Clinical Pearls for NEET-PG:** * **Cancer & Aging:** Telomerase activity is high in germ cells, stem cells, and **cancer cells** (conferring immortality), but low or absent in most somatic cells, leading to cellular senescence. * **Other Reverse Transcriptases:** Retroviruses like **HIV** utilize reverse transcriptase to integrate their viral genome into the host DNA. * **Zidovudine (AZT):** A common NEET-PG topic; it is a drug that inhibits reverse transcriptase, used in the treatment of HIV. * **Telomere Sequence:** In humans, the repeating hexanucleotide sequence is **5'-TTAGGG-3'**.

Question 6: Molybdenum is a constituent of which of the following enzymes?

A. Xanthine oxidase (Correct Answer)
B. Cytochrome oxidase
C. Phosphofructokinase
D. Carbonic anhydrase

Explanation: **Explanation:** **1. Why Xanthine Oxidase is Correct:** Xanthine oxidase is a complex metalloflavoprotein that requires **Molybdenum (Mo)** as an essential cofactor (in the form of a molybdopterin cofactor), along with FAD and Iron (Fe). This enzyme plays a critical role in purine catabolism, catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. **2. Analysis of Incorrect Options:** * **Cytochrome oxidase (Complex IV):** This terminal enzyme of the electron transport chain contains **Copper (Cu)** and **Iron (Fe)** (in heme groups). It does not require molybdenum. * **Phosphofructokinase (PFK-1):** The rate-limiting enzyme of glycolysis requires **Magnesium (Mg²⁺)** or Manganese (Mn²⁺) as a cofactor to stabilize the ATP substrate. * **Carbonic anhydrase:** This enzyme, crucial for CO₂ transport and acid-base balance, is a classic example of a **Zinc (Zn²⁺)** containing metalloenzyme. **3. High-Yield Clinical Pearls for NEET-PG:** * **Molybdenum-dependent enzymes:** Besides Xanthine oxidase, other key enzymes include **Aldehyde oxidase** and **Sulfite oxidase**. * **Clinical Correlation:** Allopurinol, used in the treatment of Gout, acts as a suicide inhibitor of Xanthine oxidase, thereby reducing uric acid production. * **Molybdenum Deficiency:** Rare, but can lead to "Sulfite Oxidase Deficiency," presenting with neurological symptoms and ectopia lentis (similar to homocystinuria). * **Other Metal Cofactors to Remember:** * **Selenium:** Glutathione peroxidase. * **Manganese:** Pyruvate carboxylase, Arginase. * **Zinc:** Alcohol dehydrogenase, DNA/RNA Polymerase, Carboxypeptidase.

Question 7: Cyanide poisoning acts by:

A. Inhibiting DNA synthesis
B. Inhibiting enzymes of protein synthesis
C. Inhibiting cellular respiration (Correct Answer)
D. Inhibiting protein breakdown

Explanation: **Explanation:** **Why the correct answer is right:** Cyanide poisoning is a classic example of **non-competitive inhibition** affecting the mitochondrial Electron Transport Chain (ETC). Cyanide ($CN^-$) binds with high affinity to the **ferric ($Fe^{3+}$) state** of iron in the **Cytochrome a-a3 complex (Complex IV)**. By binding here, it prevents the final transfer of electrons to oxygen, effectively halting the ETC. This leads to a cessation of ATP production via oxidative phosphorylation, resulting in "histotoxic hypoxia"—a state where cells cannot utilize oxygen despite its availability in the blood. **Why the incorrect options are wrong:** * **A & B (DNA and Protein Synthesis):** While cyanide eventually leads to cell death which stops all metabolic processes, it does not directly target the enzymes involved in replication, transcription, or translation. Its primary mechanism is metabolic, not biosynthetic. * **D (Protein Breakdown):** Cyanide does not inhibit proteases or the ubiquitin-proteasome pathway; its immediate lethal effect is due to the energy crisis caused by respiratory inhibition. **NEET-PG High-Yield Pearls:** * **Antidote Mechanism:** Treatment involves **Amyl Nitrite/Sodium Nitrite**, which converts hemoglobin to **methemoglobin** ($Fe^{3+}$). Methemoglobin has a higher affinity for cyanide than Cytochrome a-a3, "sequestering" the poison. This is followed by **Sodium Thiosulfate**, which converts cyanide to non-toxic thiocyanate via the enzyme **rhodanese**. * **Clinical Sign:** Patients often present with "cherry-red" skin (due to high venous oxygen saturation) and a characteristic **bitter almond odor** on the breath. * **Other Complex IV Inhibitors:** Carbon Monoxide (binds $Fe^{2+}$), Azide ($N_3^-$), and Hydrogen Sulfide ($H_2S$).

Question 8: Which of the following is a non-vitamin coenzyme?

A. Lipoic acid (Correct Answer)
B. Coenzyme A
C. S-adenosyl methionine
D. Niacin

Explanation: **Explanation:** Coenzymes are non-protein organic molecules required by enzymes for their catalytic activity. While many coenzymes are derivatives of water-soluble B-complex vitamins, several essential coenzymes are synthesized endogenously from non-vitamin precursors. **Correct Option: A. Lipoic Acid** Lipoic acid is a sulfur-containing fatty acid derivative. It acts as a coenzyme for oxidative decarboxylation reactions (e.g., Pyruvate Dehydrogenase and α-Ketoglutarate Dehydrogenase complexes). It is considered a **non-vitamin coenzyme** because the human body can synthesize it from octanoic acid and cysteine; therefore, it does not meet the strict dietary requirement definition of a vitamin. **Analysis of Incorrect Options:** * **B. Coenzyme A:** This is a vitamin-derived coenzyme synthesized from **Pantothenic acid (Vitamin B5)**. It is essential for acyl group transfer. * **C. S-adenosyl methionine (SAMe):** While SAMe is a non-vitamin coenzyme (derived from the amino acid Methionine), in the context of standard medical biochemistry exams like NEET-PG, **Lipoic acid** is the classic textbook example used to distinguish non-vitamin cofactors. *Note: If this were a multiple-select question, SAMe would also qualify, but Lipoic acid is the primary "high-yield" answer.* * **D. Niacin:** This is **Vitamin B3** itself, which serves as the precursor for the coenzymes NAD+ and NADP+. **High-Yield Clinical Pearls for NEET-PG:** * **The "Big Five" Coenzymes:** For the Pyruvate Dehydrogenase (PDH) complex, remember the mnemonic **Tender Loving Care For Nancy**: **T**PP (B1), **L**ipoic acid, **C**oA (B5), **F**AD (B2), and **N**AD (B3). * **Arsenic Poisoning:** Arsenite inhibits enzymes requiring Lipoic acid by binding to its SH (sulfhydryl) groups, leading to lactic acidosis and neurological symptoms. * **Other Non-Vitamin Coenzymes:** ATP, UDP-Glucose, Heme, and Coenzyme Q (Ubiquinone).

Question 9: Serum alkaline phosphatase levels increase in which of the following conditions?

A. Hypothyroidism
B. Carcinoma of the prostate
C. Hyperparathyroidism (Correct Answer)
D. Myocardial infarction

Explanation: **Explanation:** **Alkaline Phosphatase (ALP)** is a group of isoenzymes that catalyze the hydrolysis of organic phosphates at an alkaline pH. It is primarily found in the **liver** (biliary canaliculi) and **bone** (osteoblasts). **Why Hyperparathyroidism is correct:** In hyperparathyroidism, elevated Parathyroid Hormone (PTH) stimulates osteoclastic bone resorption. However, this is coupled with compensatory **osteoblastic activity** to repair the bone. Since ALP is a marker of osteoblastic activity, its serum levels rise significantly in conditions involving high bone turnover, such as Hyperparathyroidism, Paget’s disease, and Rickets/Osteomalacia. **Analysis of Incorrect Options:** * **Hypothyroidism:** This is associated with **decreased** ALP levels due to reduced bone turnover and metabolism. (Other causes of low ALP include Hypophosphatasia and Zinc deficiency). * **Carcinoma of the Prostate:** While this can cause elevated ALP if it metastasizes to the bone (osteoblastic metastases), the classic marker for prostate cancer is **Acid Phosphatase (ACP)** and Prostate-Specific Antigen (PSA). * **Myocardial Infarction:** The primary markers for MI are Troponins, CK-MB, and LDH-1. ALP has no significant presence in cardiac muscle. **High-Yield Clinical Pearls for NEET-PG:** * **Physiological Increase:** Seen in growing children (bone growth) and the 3rd trimester of pregnancy (placental isoenzyme). * **Heat Stability:** To differentiate the source of ALP, remember: *"Regan is Heat Stable"* (Placental/Cancer isoenzymes are heat-stable, while Bone ALP is heat-labile). * **Biliary Marker:** ALP is the most sensitive marker for **obstructive jaundice** (cholestasis).

Question 10: In myocardial infarction, which enzyme is typically elevated within 4 to 6 hours and returns to normal levels in 3 to 4 days?

A. AST (SGOT)
B. LDH
C. CK-MB (CPK) (Correct Answer)
D. ALT (SGPT)

Explanation: **Explanation:** The correct answer is **CK-MB (CPK)**. In the context of Myocardial Infarction (MI), cardiac biomarkers follow a specific temporal pattern of rise, peak, and decline, which is high-yield for NEET-PG. **1. Why CK-MB is correct:** CK-MB (Creatine Kinase-MB) is a relatively specific isoenzyme for cardiac muscle. Following myocardial injury, it begins to rise within **4 to 6 hours**, reaches its peak at 18 to 24 hours, and typically returns to baseline within **48 to 72 hours (2 to 3 days)**. Because of its rapid clearance, it is the gold-standard marker for detecting **re-infarction** occurring shortly after the initial event. **2. Why other options are incorrect:** * **AST (SGOT):** It rises within 8–12 hours and returns to normal in 4–5 days. It is less specific than CK-MB as it is also found in the liver and skeletal muscle. * **LDH (Lactate Dehydrogenase):** This is a late marker. It begins to rise after 24 hours, peaks at 3–6 days, and remains elevated for **8–14 days**. It is useful for late diagnosis of MI. * **ALT (SGPT):** Primarily a marker for hepatocellular injury; it has minimal diagnostic value for MI. **3. Clinical Pearls for NEET-PG:** * **Troponin I & T:** These are the most sensitive and specific markers for MI. They rise within 3–4 hours but remain elevated for **7–10 days (Troponin I)** or **up to 14 days (Troponin T)**. * **Myoglobin:** The **earliest** marker to rise (within 1–3 hours), but it lacks specificity as it is also present in skeletal muscle. * **Order of appearance:** Myoglobin > CK-MB/Troponins > AST > LDH.

Practice by Chapter

Enzyme Classification and Nomenclature

Practice Questions

Enzyme Kinetics and Michaelis-Menten Equation

Practice Questions

Enzyme Inhibition: Competitive and Non-competitive

Practice Questions

Allosteric Regulation

Practice Questions

Coenzymes and Cofactors

Practice Questions

Isoenzymes and Clinical Significance

Practice Questions

Enzyme Regulation: Covalent Modification

Practice Questions

Enzyme Regulation: Zymogen Activation

Practice Questions

Enzyme Induction and Repression

Practice Questions

Ribozymes and Catalytic RNA

Practice Questions

Enzyme Diagnostic Applications

Practice Questions

Enzyme Therapy and Inhibitors as Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Enzymes — MCQs

Enzymes — MCQs

On this page

Practice by Chapter

Want unlimited practice?